Global Genomics Partnering Terms and Agreements Report 2016 to 2023: Disclosed Headlines, Upfronts, Milestones and Royalties by Stage of Development

News provided by

Jun 22, 2023, 11:30 ET

DUBLIN, June 22, 2023 /PRNewswire/ -- The "Global Genomics Partnering Terms and Agreements 2016 to 2023" report has been added to ResearchAndMarkets.com's offering.

The Global Genomics Partnering Terms and Agreements 2016 to 2023 report provides an understanding and access to the genomics partnering deals and agreements entered into by the world's leading healthcare companies.

Trends in genomics partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Genomics partnering contract documents
Top genomics deals by value

The Global Genomics Partnering Terms and Agreements report provides an understanding and access to the genomics partnering deals and agreements entered into by the world's leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter genomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors genomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual genomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of genomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in genomics dealmaking since 2016, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading genomics deals since 2016. Deals are listed by headline value, signed by big pharma, most active genomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in genomics dealmaking with a brief summary followed by a comprehensive listing of genomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of genomics partnering deals signed and announced since Jan 2016, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of genomics partnering deals signed and announced since Jan 2016. The chapter is organized by specific genomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by genomics partnering company A-Z, deal type definitions and genomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in genomics partnering and dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of genomics technologies and products.

Report scope

Global Genomics Partnering Terms and Agreements 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to genomics trends and structure of deals entered into by leading companies worldwide.

Global Genomics Partnering Terms and Agreements 2016 to 2023 includes:

Trends in genomics dealmaking in the biopharma industry since 2016
Access to headline, upfront, milestone and royalty data
Access to over 800 genomics deal records and contract documents where available
The leading genomics deals by value since 2016
Most active genomics dealmakers since 2016
The leading genomics partnering resources

In Global Genomics Partnering Terms and Agreements 2016 to 2023, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in genomics dealmaking
2.1. Introduction
2.2. Genomics partnering over the years
2.3. Most active genomics dealmakers
2.4. Genomics partnering by deal type
2.5. Genomics partnering by therapy area
2.6. Deal terms for genomics partnering
2.6.1 Genomics partnering headline values
2.6.2 Genomics deal upfront payments
2.6.3 Genomics deal milestone payments
2.6.4 Genomics royalty rates

Chapter 3 - Leading genomics deals
3.1. Introduction
3.2. Top genomics deals by value

Chapter 4 - Most active genomics dealmakers
4.1. Introduction
4.2. Most active genomics dealmakers
4.3. Most active genomics partnering company profiles

Chapter 5 - Genomics contracts dealmaking directory
5.1. Introduction
5.2. Genomics contracts dealmaking directory

Chapter 6 - Genomics dealmaking by technology type

Companies Mentioned

1CellBiO
2bPrecise
2seventy bio
3 Sisters Surrogacy
3D Signatures
4baseCare
10X Genomics
14M Genomics
22nd Century
23andMe
A*STAR Agency for Science
Technology and Research
A*STAR Bioinformatics Institute
A*STAR Genome Institute of Singapore
Abbvie
Abcam
Abramson Cancer Center
Absorption Systems
Academia Sinica
Accelerated Cure Project for MS
Accelerate Technologies
Access to Comprehensive Genomic Profiling Coalition
Acerta Pharma
ACMG Foundation for Genetic and Genomic Medicine
ACT Genomics
Active Motif
ActX
Adaptimmune
Adaptive Biotechnologies
ADInstruments
Admera Health
Adrestia
Advaita
ADx Healthcare
Aelan Cell Technologies
Aevi Genomic Medicine
Affymetrix
AgBiome
Agendia
Agilent Technologies
Agribody Technologies
Agriplex Genomics
AiLife Diagnostics
Aitbiotech
Akadeum Life Sciences
AKESOgen
Alana Healthcare
Albany Molecular Research
Alexion Pharmaceuticals
AllCells
Allele Biotechnology and Pharmaceuticals
Almac Diagnostics
Alnylam Pharmaceuticals
ALS Association
ALS Automated Lab Solutions
Altor BioScience
Alzheimer's Drug Discovery Foundation
Amazon Web Services
Ambry Genetics
America's Choice Provider Network
American Physiological Society
American Society of Clinical Oncology (ASCO)
American Type Culture Collection (ATCC)
Amgen
Amplicon Express
Analytical BioSciences
Anam Hospital
Angsana Molecular & Diagnostics
AnimalBiome
Annoroad
APG Bio
Applied Biosystems
Aptorum Group
Arbor Biotechnologies
Arcadia Biosciences
Arc Bio
ArcherDX
Arcturus Therapeutics
Argonaut
Arima Genomics
Arzeda
Aslan Pharma
Astellas Pharma
AstraZeneca
Astrea Forensics
Athletigen
Atlas Genetics
Atlas Genomics
ATUM
Auria Biobank
Avance Biosciences
Avera Health
Avera Heart Hospital of South Dakota
Avvinity Therapeutics
Axil Scientific
B-MoGen Biotechnologies
Baheal Pharmaceutical
Bank of America
Banner Health
BASF
Battelle
Bayer
Bayer CropScience
Bayer Healthcare
Baylor College of Medicine
Baylor Genetics
Baylor Miraca Genetics Laboratories
BC Platforms
BD Biosciences
Beckman Coulter
Becton Dickinson
Beijing Genomics Institute (BGI)
Beijing InnoCare Pharma
Belgian Society of Medical Oncology
Benson Hill Biosystems
Berkeley Lights
Berry Genomics
Beth Israel Deaconess Medical Center
BGI
BGI Americas
Bill and Melinda Gates Foundation
Bina Technologies
Bio-Rad Laboratories
Bio-Techne
BioBright
Biocartis
Biocept
Biodesix
BioDiscovery
BioFire Diagnostics
Biogen
BioIntelliSense
BioIQ
BioLegend
BioMap
BioMarin Pharmaceutical
Biomecite Diagnostics
Biomedical Advanced Research and Development Authority
BioMed X Innovation Center
Biomillenia
BioNano Genomics
BioNova Cientifica
BioReference Laboratories
BioSkryb
Biosplice
Biostar
BioTheranostics
Biotop
Blackfynn
Blockchain Global
Bluebird Bio
Blue Cross Blue Shield Association

For more information about this report visit https://www.researchandmarkets.com/r/oruo9x

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets